We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

143 hedge funds and large institutions have $212M invested in Viking Therapeutics in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 50 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $4.78M | Put options by funds: $2.87M

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

2% more funds holding

Funds holding: 140 → 143 (+3)

2.64% less ownership

Funds ownership: 54.37% → 51.73% (-2.6%)

8% less capital invested

Capital invested by funds: $230M → $212M (-$17.6M)

12% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 50

Holders
143
Holders Change
+3
Holders Change %
+2.14%
% of All Funds
2.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
44
Reduced
50
Closed
17
Calls
$4.78M
Puts
$2.87M
Net Calls
+$1.91M
Net Calls Change
-$3.6M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.67M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$3.14M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$2.31M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.37M
5
Group One Trading
Group One Trading
Illinois
+$1.14M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.69M
2
Goldman Sachs
Goldman Sachs
New York
-$3.31M
3
DM
Deerfield Management
New York
-$2.03M
4
Morgan Stanley
Morgan Stanley
New York
-$1.55M
5
UBS Group
UBS Group
Switzerland
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
DGI
76
Disciplined Growth Investors
Minnesota
$113K +$121K +20,000 New
CANY
77
Caxton Associates (New York)
New York
$112K +$121K +19,901 New
TI
78
Trexquant Investment
Connecticut
$111K -$253K -41,702 -68%
Stifel Financial
79
Stifel Financial
Missouri
$111K -$4.74K -782 -4%
WS
80
Wedbush Securities
California
$107K -$15.1K -2,500 -12%
ASRS
81
Arizona State Retirement System
Arizona
$107K -$4.51K -744 -4%
IGGA
82
Iron Gate Global Advisors
Utah
$107K – – –
CIP
83
Cornerstone Investment Partners
Georgia
$100K – – –
Citigroup
84
Citigroup
New York
$97K +$28.5K +4,711 +38%
CL
85
CSS LLC
Illinois
$96K – – –
ACI
86
AMP Capital Investors
Australia
$95K +$98.7K +16,300 New
HF
87
HRT Financial
New York
$94K +$102K +16,801 New
Arrowstreet Capital
88
Arrowstreet Capital
Massachusetts
$92K +$98.7K +16,300 New
MFA
89
Mayflower Financial Advisors
Massachusetts
$89K +$95.6K +15,778 New
OAM
90
Oppenheimer Asset Management
New York
$87K -$1.53K -253 -2%
SFWA
91
Summit Financial Wealth Advisors
Louisiana
$85K -$1.21K -200 -1%
Principal Financial Group
92
Principal Financial Group
Iowa
$85K +$1.99K +329 +2%
ProShare Advisors
93
ProShare Advisors
Maryland
$82K +$88K +14,526 New
LPL Financial
94
LPL Financial
California
$81K – – –
CPA
95
Court Place Advisors
Maryland
$78K – – –
IFWM
96
Institute for Wealth Management
Colorado
$70K +$1.28K +211 +2%
KAS
97
Kestra Advisory Services
Texas
$69K -$5.45K -900 -7%
Thrivent Financial for Lutherans
98
Thrivent Financial for Lutherans
Minnesota
$64K – – –
Qube Research & Technologies (QRT)
99
Qube Research & Technologies (QRT)
United Kingdom
$63K -$63.1K -10,415 -48%
TRCT
100
Tower Research Capital (TRC)
New York
$61K +$4.14K +684 +7%
2 3
4
5 6

VKTX Hedge Fund Activity: Q4 2020 in Review

143 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2020, worth a combined $212M — down 7.7% from $230M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new VKTX positions and 17 closed out — a net gain of 3 holders — while 44 added to existing stakes and 50 trimmed.

The largest buyer was BlackRock, adding an estimated $3.67M. The largest seller was Fidelity Investments, cutting an estimated $9.69M.

  • 143 institutional investors held Viking Therapeutics (VKTX) as of Q4 2020, up from 140 in Q3 2020.
  • Funds reported $212M of Viking Therapeutics stock for Q4 2020, down 7.7% quarter-over-quarter.
  • 20 funds opened new Viking Therapeutics positions in Q4 2020 and 17 closed out, a net change of +3 holders.
  • The largest Viking Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.67M added.
  • The largest Viking Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $9.69M sold.

Based on aggregated 13F filings for Q4 2020.